multiple trials have demonstrated that the sirolimus and paclitaxel drug-eluting stents markedly reduced the incidence of in-stent restenosis and the rate of target lesion revascularization by about 75 percent.
A 2006 meta-analysis included 19 trials with 7060 patients comparing DES to BMS:
No effect on all-cause mortality
A significant reduction in angiographic restenosis (10.5 versus 31.7 percent)
A significant reduction in target lesion revascularization (6.2 versus 16.6 percent)
A significant reduction in major adverse cardiac events (10.1 versus 19.9 percent), which was entirely due to a reduction in target lesion revascularization.
BUT there are safety concerns, cost issues and the need for patients to received long-term dual antiplatelet therapy is an issue
references and resources
c_stents.txt · Last modified: 2009/03/03 04:42 (external edit)